{"id":7267,"date":"2013-06-05T03:50:43","date_gmt":"2013-06-05T07:50:43","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=7267"},"modified":"2013-06-05T03:50:43","modified_gmt":"2013-06-05T07:50:43","slug":"rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267","title":{"rendered":"Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) focus on intracellular pathways"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 06\/05\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) had declined by 18.10 percent to close at $3.71 per share. The shares of the company had been trading in the range of $3.56 to $4.04 per share during the day. With this continuous decline in share prices, Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) had plunged to new lows with the 52 week low price level of the company recorded at $3.56 per share and the 52 week high price level of the company is at $11.44 per share.<\/p>\n<p style=\"text-align: justify;\">Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) is involved in the development and commercialization of drugs for the treatment of muscular disorders, inflammatory diseases and autoimmune diseases. The clinical stage drug development company conducts various researches for the development of drugs and treatment therapies with special focus on intracellular signaling pathways and other related targets which are highly critical to disease mechanisms.<\/p>\n<p style=\"text-align: justify;\">The shares of the clinical stage drug development company, Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) had been declining in prices at heavy trading volumes in the recent days. Such volumes and combining decline in share prices had led the company to slide to new bottoms with the recent low being $3.56 per share.<\/p>\n<p style=\"text-align: justify;\">Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) had witnessed a trading volume of 6.01 million shares on the trading session of Tuesday, while the average trading volume for the company is at 800,857 shares per day. The company presently holds 87.14 million shares outstanding in the market with an institutional ownership of 94 percent of its holdings.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 06\/05\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) had declined by 18.10 percent to close at $3.71 per share. The shares [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":7268,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2477,2476],"stock_ticker":[],"class_list":["post-7267","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqrigl","tag-rigel-pharmaceuticals-inc-nasdaqrigl","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) focus on intracellular pathways - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) focus on intracellular pathways - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 06\/05\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) had declined by 18.10 percent to close at $3.71 per share. The shares [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-06-05T07:50:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Rigel___Wallpaper__eXtra_by_serdarguler.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) focus on intracellular pathways\",\"datePublished\":\"2013-06-05T07:50:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267\"},\"wordCount\":254,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Rigel___Wallpaper__eXtra_by_serdarguler.jpg\",\"keywords\":[\"NASDAQ:RIGL\",\"Rigel Pharmaceuticals Inc. (NASDAQ:RIGL)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267\",\"name\":\"Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) focus on intracellular pathways - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Rigel___Wallpaper__eXtra_by_serdarguler.jpg\",\"datePublished\":\"2013-06-05T07:50:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Rigel___Wallpaper__eXtra_by_serdarguler.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Rigel___Wallpaper__eXtra_by_serdarguler.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) focus on intracellular pathways\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) focus on intracellular pathways - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267","og_locale":"en_US","og_type":"article","og_title":"Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) focus on intracellular pathways - Wall Street PR","og_description":"Boston, MA 06\/05\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) had declined by 18.10 percent to close at $3.71 per share. The shares [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-06-05T07:50:43+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Rigel___Wallpaper__eXtra_by_serdarguler.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) focus on intracellular pathways","datePublished":"2013-06-05T07:50:43+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267"},"wordCount":254,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Rigel___Wallpaper__eXtra_by_serdarguler.jpg","keywords":["NASDAQ:RIGL","Rigel Pharmaceuticals Inc. (NASDAQ:RIGL)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267","url":"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267","name":"Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) focus on intracellular pathways - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Rigel___Wallpaper__eXtra_by_serdarguler.jpg","datePublished":"2013-06-05T07:50:43+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Rigel___Wallpaper__eXtra_by_serdarguler.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Rigel___Wallpaper__eXtra_by_serdarguler.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/rigel-pharmaceuticals-inc-nasdaqrigl-focus-on-intracellular-pathways-7267#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) focus on intracellular pathways"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/7267","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=7267"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/7267\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/7268"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=7267"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=7267"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=7267"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=7267"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}